AbbVie Signs $3.9 Billion Oncology Deal with Genmab
The partners will develop and hopefully commercialize up to seven new cancer drugs.
Genmab A/S(GMAB)
Nasdaq Global Select
GMAB
$36.44
-$0.80
-2.1%
Price as of August 16, 2022, 3:00 p.m. ET
View Interactive GMAB Charts
Genmab has developed multiple technologies for creating antibody-based drugs, generates revenue through royalties on partner-produced drugs, and has a robust pipeline to feed future growth.
Interactive Chart
Compare GMAB Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
|---|---|---|---|---|
|
GMAB
Genmab A/S
|
$36.44 | $24B | -19.6% | 72.2% |
|
ILMN |
$219.83 | $35B | -56.8% | 16.7% |
|
BMY |
$74.13 | $158B | 11.9% | 50.7% |
|
EXEL |
$19.51 | $6B | 4.9% | -27.6% |
|
GILD |
$66.33 | $83B | -3.4% | 9.0% |
News & Analysis: Genmab A/S
Are There Good Investments Among 2019's Biotech IPOs?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
